Cost‐effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO‐AD trial)

Objective Most investigations of pharmacotherapy for treating Alzheimer's disease focus on patients with mild‐to‐moderate symptoms, with little evidence to guide clinical decisions when symptoms become severe. We examined whether continuing donepezil, or commencing memantine, is cost‐effective...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of geriatric psychiatry 2017-12, Vol.32 (12), p.1205-1216
Hauptverfasser:	Knapp, Martin, King, Derek, Romeo, Renée, Adams, Jessica, Baldwin, Ashley, Ballard, Clive, Banerjee, Sube, Barber, Robert, Bentham, Peter, Brown, Richard G, Burns, Alistair, Dening, Tom, Findlay, David, Holmes, Clive, Johnson, Tony, Jones, Robert, Katona, Cornelius, Lindesay, James, Macharouthu, Ajay, McKeith, Ian, McShane, Rupert, O'Brien, John T, Phillips, Patrick P J, Sheehan, Bart, Howard, Robert
Format:	Artikel
Sprache:	eng
Schlagworte:	Activities of Daily Living Aged Aged, 80 and over Alzheimer Disease - drug therapy Alzheimer Disease - economics Alzheimer's disease Cholinesterase Inhibitors - economics Cholinesterase Inhibitors - therapeutic use Clinical trials Cognition Cost analysis Cost-Benefit Analysis cost‐effectiveness Donepezil Double-Blind Method England Female Geriatric psychiatry Health Care Costs Humans Indans - economics Indans - therapeutic use Memantine Memantine - economics Memantine - therapeutic use Neurodegenerative diseases Piperidines - economics Piperidines - therapeutic use Quality of Life Wales
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!